Molbio Diagnostics Ltd Company Fundamental Analysis

Molbio Diagnostics is a molecular diagnostics company focused on decentralised point-of-care testing, with its flagship Truenat platform offering portable, battery-powered PCR testing for infectious and non-communicable diseases. The business has a differentiated product ecosystem covering analysers, test kits and associated consumables, with recurring demand from test-kit usage. Its technology is particularly relevant for settings where centralised laboratory infrastructure is limited. The business delivered a sharp recovery in Q1 FY27. Consolidated total income increased to ₹411.5 crore from ₹100.5 crore in Q1 FY26, while EBITDA moved from a ₹14.5 crore loss to ₹103.7 crore, giving a 25.2% EBITDA margin. PAT improved from a ₹23.9 crore loss to ₹52.7 crore. The company highlighted continued growth in Truenat test-kit consumption as a key driver. FY26 revenue was approximately ₹1,446 crore, with ROE around 15% and ROCE around 18–20%. However, operating cash flow and working-capital requirements remain areas worth monitoring as the business scales. Growth opportunities include greater adoption of molecular testing, expansion into international markets, increasing test-kit consumption and utilisation of recently expanded manufacturing and R&D capacity. The IPO proceeds are also being deployed toward R&D/Center of Excellence infrastructure and additional plant and machinery. At the latest Groww snapshot, market capitalisation was around ₹14,361 crore, P/E 87.5x, P/B 10.5x, ROE 14.25% and debt-to-equity 0.38x. The major risks are high valuation relative to current earnings, dependence on Truenat adoption and public-health/export orders, execution of capacity expansion and potentially uneven quarterly revenue due to order timing. The recent turnaround in profitability is significant, but sustaining high growth and improving capital efficiency will be important for the business to justify its current valuation.